

Supplementary Information For

LC-MS/MS quantification of sulfotransferases is better than conventional immunogenic methods in determining human liver SULT activities: implication in precision medicine

Cong Xie^{1, 2#}, Tong-meng Yan^{2, 5#}, Jia-mei Chen², Xiao-yan Li², Juan Zou², Li-jun Zhu², Linlin Lu², Ying Wang², Fu-yuan Zhou^{3, 2*}, Zhong-qiu Liu^{1, 2*}, Ming Hu^{4*}

¹Department of Pharmaceutics, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China, 510515.

²International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China, 510006.

³Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, 510515.

⁴Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77030, USA.

⁵State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau (SAR), China.

Table of Contents:

Table S1. Characteristics of peptides for quantification of SULTs

Table S2. MRM transitions of peptides for quantifying SULTs enzymes

Table S3. Incubation Conditions for SULT Activity Assays

Table S4. Analytical Parameters for Activity Assays of SULTs

Table S5. PCR Primers for Human SULT Enzymes and GADPH

Table S6. Protein expression levels of SULT enzymes in human liver S9 fraction

Table S7. Intra-and inter-day precision and accuracy for the determination of SULTs

Table S8. Extraction recovery of signature peptides for quantifying SULTs enzymes

Table S9. Validation for LC-MS/MS quantification of protein amount of SULTs using standard addition method

Figure of Contents:

Fig. S1. The procedure of selecting the unique peptides for the MRM

UHPLC-MS/MS.

Fig. S2. The peptide of the MS/MS spectra of SULT1A1, SULT1A3, SULT1B1,

SULT1E1 and SULT2A1, in respectively, obtained from ESI-MS in positive.

ionization mode.

Fig. S3. The MS² spectrograms of prototypic peptides measured in the present study.

Fig. S4. Standard curves of prototypic peptides for quantifying SULT enzymes.

Fig. S5. Western blot analysis the protein expression levels of 5 SULTs enzymes in

healthy human liver S9 from 10 individual donors.

Table S1. Characteristics of peptides for quantification of SULTs enzymes.

Isoforms	Sequence	Length (AA)	Mass (Da)	Unipro Entry
SULT1B1	V ₁₆₈ AYGSWFTHVK ₁₇₈	11	1293.65	O43704
SULT1E1	L ₃₉ IHFLEK ₄₅	7	926.53	Q53X91
SULT2A1	W ₃₄ IQSVPIWER ₄₄	10	1304.69	A8K015
SULT1A2	V ₁₄₈ YHPGTWESFLEK ₁₆₁	14	1688.82	E9PKR8
SULT1A1	T ₁₀₇ HLPLALLPQTLLDQK ₁₂₂	16	1800.05	H3BRY5
SULT1A3	A ₇₄ HPEPGTWDSFLEK ₈₇	14	1612.75	H3BPL6

Table S2. MRM transitions of peptides for quantifying SULT enzymes.

Isoforms	Quantitative Ions			Qualitative Ions		
	MRM Transitions	Ion Series ^a	CE ^b	MRM Transitions	Ion Series ^a	CE ^b
SULT2A1	657.5>700.5	y5	16	657.5>1014.3	y8	20
	657.5>272.3	a2	20	657.5>886.5	y7	20
SULT1A1	601.1>471.6	y5*	8	601.1>859.8	b8	12
	601.1>746.3	b7	16			
SULT1A2	564.1>714.4	y12	8	564.1>263.0	b2	8
	564.1>225.2	a2	20	564.1>666.2	a11	16
SUT1A3	538.8>532.6	b5	4	538.8>290.0	b2	20
	538.8>690.0	b7	8	538.8>738.8	y6	8
SULT1B1	432.2>562.8	y6	8	432.2>158.7	b3	24
	432.2>171	b2	12			
SULT1E1	309.8>408.0	y6	12	309.8>175.1	y1	12
	309.8>564.2	y4	12			
Pep-IS	565.0>398.2	y ⁰³	12	565.0>221.1	b2	26
	565.0>795.4	y7	15	565.0>454.9	y ⁸⁺	22

^a: The nomenclature, reported by Roepstorff ¹ and Johnson ² for fragment ions in mass spectrum of signature peptides was used.

^b: CE: collision energy

Table S3. Incubation conditions for SULT activity assays.

Isoform	Probe Substrate	Substrate Conc. ^a (μ M)	Substrate Range ^b (μ M)	Protein Conc. (mg/ml)	Incubation Time (min)	Metabolite
SULT1A1	p-Nitrophenol	1	0.125-40	0.25	30	Potassium 4-nitrophenyl sulfate
SULT1A3 [#]	Dopamine	0.625	0.25-300	0.5	30	Dopamine 3-O-Sulfate
SULT1A3 [#]	Dopamine	0.625	0.25-300	0.5	30	Dopamine 4-O-Sulfate
SULT1B1	2-Aminophenol	2.5	0.25-40	0.25	30	2-aminophenol sulfate
SULT1E1	17 β -estradiol	10	0.3125-40	0.25	30	17 β -estradiol 3-sulfate
SULT2A1	DHEA ^c	1	0.125-20	0.25	30	Dehydroisoandrosterone 3-sulfate sodium

a: A specific concentration of substrate was used for determining SULT activity of each patient.

b: A range concentration of substrate was used for determining kinetic profile of SULT in human liver S9.

c: DHEA: Dehydroisoandrosterone

[#]: Dopamine was the probe substrate of the SULT1A3. Dopamine has two isomeric metabolites in phase II

Table S4. Analytical parameters for activity assays of SULTs.

Parameters (LC-MS/MS)	SULT1A1	SULT1A3	SULT1B1	SULT1E1	SULT2A1
Analyte	p-Nitrophenol	Dopamine	2-Aminophenol	17 β -estradiol	DHEA ^b
Injection volume(μ l)	1	1	1	1	1
Mobile phase(A/B)	Ammonium acetate /ACN ^a	Ammonium acetate /ACN	Ammonium acetate /ACN	Ammonium acetate /ACN	Ammonium acetate /ACN
Gradient program (%B(min))	20(0) \rightarrow 45(2) \rightarrow 45(6) \rightarrow 20(6.1-7)	5(0-2) \rightarrow 70(3.9) \rightarrow 70(7) \rightarrow 5(7.1-8)	5(0) \rightarrow 45(2) \rightarrow 45(5) \rightarrow 5(5.1-6)	20(0) \rightarrow 45(2) \rightarrow 45(4) \rightarrow 20(4.1-5)	20(0) \rightarrow 45(2) \rightarrow 45(4) \rightarrow 20(4.1-5)
Analyte transition	217.97>138	231.8>151.90	188>108	351.10>271.20	367.10>97
Collision energy(V)	8	20	20	32	48
Cell accelerator voltage(V)	4	5	2	5	4
Retention time (min)	3.851	2.330 [#] 2.720 [#]	1.543	2.443	2.637
Internal standard	PS ^c	PS	PS	PS	PS

a:ACN:acetonitrile. #: The retention time 2.330 is the dopamine-4-O-Sulfate and the 2.720 is the dopamine-3-O-Sulfate.

b: DHEA: Dehydroepiandrosterone c: pregnenolone sulfate

Table S5. PCR primers for human SULT enzymes and GAPDH.

GAPDH	forward	GGCCTCCAAGGAGTAAGACC
	reverse	AGGGGAGATTCAGTGTGGTG
SULT1A1	forward	AAAGCCCCAGGGATTCCCTCA
	reverse	GGAAACTGCCACATCCTTTGCGT
SULT1A3	forward	CGATGCGGACTATGCGGAGAAG
	reverse	GACATGAGCCACTGTGCCTGAC
SULT1B1	forward	GCTGGTGACTGGAAGAATTACT
	reverse	GAAGAGCCTGTGGTTACATTGT
SULT1E1	forward	GGCTGGTCATCCAAATCCTGG
	reverse	AGGAACCATAAGGAACCTGTCC
SULT2A1	forward	TCGTGATAAGGGATGAAGATGTAATAA
	reverse	TGCATCAGGCAGAGAATCTCA

Table S6 Protein expression levels of SULT enzymes in human liver S9 fraction.

The expression of enzymes was determined in human liver S9 from 10 donors. Each value represents the mean \pm SD (n=10).

Enzyme	No. of Quantified Donor	Protein Amounts				Relative Protein Expression Level				Correlation (^a r ²)
		Mean	Max	Min	Max/Min	Mean	Max	Min	Max/Min	
		pmol/mg protein				relative protein expression level/ GAPDH				
SULT1A1	10	23.65 \pm 12.93	48.54	12.14	4.0	0.55 \pm 0.31	1.06	0.24	4.4	0.899 ^b
SULT1A3	10	5.18 \pm 2.04	8.79	2.2	4.0	0.33 \pm 0.07	0.44	0.24	1.8	0.492
SULT1B1	10	5.39 \pm 2.22	8.82	1.81	4.9	0.21 \pm 0.05	0.29	0.14	2.1	0.764 ^b
SULT1E1	10	2.39 \pm 0.94	4.19	1.51	2.8	0.49 \pm 0.16	0.65	0.20	3.2	0.691 ^b
SULT2A1	10	63.56 \pm 19.89	90.99	31.12	3.0	0.46 \pm 0.13	0.69	0.28	2.5	0.546

Max: maximum, Min: minimum, we used the isotope label-free LC-MS/MS to quantify protein amounts of the SULTs. And we used the western blot analysis to semi-quantify the relative protein expression levels of the same SULTs in the human liver S9 prepared from the 10 donor.

a r²: Pearson or Spearman correlation coefficient

b: Statistical significance of association ($P < 0.05$)

Table S7. Table 4 Intra-and inter-day precision and accuracy for the determination of SULTs

Isoforms	LLOQ (nM)	Accuracy (%Deviation)			Intra-day Precision(%RSD)			Inter-day Precision(%RSD)		
		Low	Mid	High	Low	Mid	High	Low	Mid	High
SULT2A1	0.3	3.0	5.7	6.7	-4.5	-9.6	-1.3	-3.6	-13.9	-3.8
SULT1A1	0.4	6.0	8.3	2.6	-0.7	-7.4	1.1	-1.2	-8.9	-1.2
SULT1A3	0.5	4.0	5.4	5.4	-10.8	8.5	-2.5	-9.2	9.6	-7.0
SULT1B1	0.8	12.5	7.5	5.2	-10.3	-16.2	-11.0	-18.1	-16.7	-9.4
SULT1E1	0.3	4.4	3.5	2.6	-11.5	-10.6	0.5	-16.1	-11.0	-1.2

Precision and accuracy were which for the determination of SULT isoforms. Intra- and Inter-Day precision and accuracy were determined by measuring standard samples at three concentration levels (Low, Mid, High): 1.56, 12.5, 100nM for all the signature peptides.

Table S8: Extraction recovery of signature peptides for quantifying SULTs enzymes

Isoforms	Recovery (%) (mean \pm SD, n=3)		
	Low	Mid	High
SULT2A1	106.2 \pm 20.3	84.3 \pm 5.1	87.8 \pm 4.3
SULT1A1	109.7 \pm 6.1	92.5 \pm 3.9	107.3 \pm 1.5
SULT1A3	97.9 \pm 6.3	79.7 \pm 6.6	80.9 \pm 8.5
SULT1B1	80.2 \pm 10.5	81.2 \pm 1.8	88.7 \pm 4.2
SULT1E1	85.9 \pm 4.8	93.1 \pm 5.0	98.6 \pm 1.8

Table S9: Validation for LC-MS/MS quantification of protein amount of SULTs using standard addition method

Isoforms	Amount in HLS9 (mean \pm SD,n=4,pmol/sample)	Spiked amount of peptide (pmol/mg)	Calculated amount of spiked peptide (pmol/mg)	Inaccuray (%Deviation)
SULT2A1	23.6 \pm 2.5	29.6	6.0	4%
SULT1A1	17.8 \pm 1.0	24.1	6.3	2%
SULT1A3	5.9 \pm 0.7	11.4	5.5	12%
SULT1B1	5.2 \pm 0.2	10.7	5.6	11%
SULT1E1	0.9 \pm 0.0	7.1	6.2	1%

Supplementary Figures




Figure S1. The full protein sequences for the SULT1A1, SULT1A2, SULT1A3, SULT1B1, SULT1E1 and SULT2A1 were obtained in batches from UniprotKB database and take them in the silico peptide digestion and excluded their' regions of uncertainty. The uniqueness of peptide sequences was verified by using BLAST search analysis. And, we developed the isotope label-free UHPLC-MS/MS for the quantification of SULTs in human liver S9.




Figure S2. The peptide of the MS/MS spectra of m/z 601.1, +3-charged THLPLALLPQTLLDQK, m/z 538.8, +3-charged AHPEPGTWDSFLEK, m/z 432.2, +3-charged VAYGSWFTHVK, m/z 309.8, +3-charged LIHFLEK, m/z 657.5, +2-charged WIQSVPIWER, m/z 564.1, +3-charged VYPHPGTWESFLEK, which were representative of the (a) SULT1A1, (b) SULT1A3, (c) SULT1B1, (d) SULT1E1, (e) SULT2A1, (f) SULT1A2 in respectively, obtained from ESI-MS in positive ionization mode. Arrows indicate optimum product ions for use in MRM transitions.

















Figure S3. The a1-g1 showed that MRM chromatograms of SULT1A1, SULT1A2, SULT1A3, SULT1B1, SULT1E1, SULT2A1 and Internal Standard (IS). The a2-g2 showed that MS² spectrograms of prototypic peptides. The red bar graph was the highest sensitivity transition for the quantitative ion.




Figure. S4. Standard curves of prototypic peptides for quantifying SULT enzymes, which were representative of the (a) SULT1A1, (b) SULT1A3, (c) SULT1B1, (d) SULT1E1 and (e) SULT2A1, respectively.









Figure S5. We used the Western blot analysis to semi-quantify the SULTs enzymes such as the SULT1A1, SULT2A1, SULT1B1, SULT1E1 and SULT1A3 in healthy human liver S9 from 10 individual donors. M: male. F: female. GAPDH was used for normalization.

References

- 1 Roepstorff, P. & Fohlman, J. Proposal for a common nomenclature for sequence ions in mass spectra of peptides. *Biomedical mass spectrometry* **11**, 601, doi:10.1002/bms.1200111109 (1984).
- 2 Johnson, R. S., Martin, S. A., Biemann, K., Stults, J. T. & Watson, J. T. Novel fragmentation process of peptides by collision-induced decomposition in a tandem mass spectrometer: differentiation of leucine and isoleucine. *Analytical chemistry* **59**, 2621-2625 (1987).